Compare 10X Genomics Inc (TXG) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? 10X Genomics Inc trades at $78.75 (market cap $10.07B), while Consumer Staples Select Sector SPDR Fund trades at $83.2 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| TXG | XLP | |
|---|---|---|
Market Cap | $10.07B | $13.50B |
Volume | 5,657,286 | 14,599,953 |
Sector | Health | — |
52-Week High | $97.74 | $90.00 |
52-Week Low | $11.48 | $75.61 |
Typical Hold Time | 92 Days | 72 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
XLP trades at $81.70, showing slight weakness with a 0.09% decline amid bearish technical signals. The ETF maintains strong analyst support with a 100% buy rating from 2 analysts, though technical indicators show moving averages and overall signals are bearish. Recent news highlights XLP's defensive characteristics and competitive expense ratio advantage over peers.
The consumer staples ETF offers defensive exposure during market volatility, supported by positive sector performance in 2026. Key risks include interest rate sensitivity and potential consumer spending slowdowns. Analyst consensus remains bullish despite technical headwinds, positioning XLP as a core defensive holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
